JAKAFI Drug Patent Profile

Which patents cover Jakafi, and what generic alternatives are available?

Jakafi is a drug marketed by Incyte Corp and is included in one NDA. There are eight patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and thirty-six patent family members in forty-six countries.

The generic ingredient in JAKAFI is ruxolitinib phosphate. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ruxolitinib phosphate profile page.

DrugPatentWatch^® Generic Entry Outlook for Jakafi

Jakafi was eligible for patent challenges on November 16, 2015.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 12, 2028. This may change due to patent challenges or generic licensing.

There have been four patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for JAKAFI

International Patents:	236
US Patents:	8
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for JAKAFI

Paragraph IV (Patent) Challenges for JAKAFI

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
JAKAFI	Tablets	ruxolitinib phosphate	5 mg, 10 mg, 15 mg, 20 mg, and 25 mg	202192	1	2015-12-17

US Patents and Regulatory Information for JAKAFI

JAKAFI is protected by eight US patents and six FDA Regulatory Exclusivities.

This potential generic entry date is based on patent 8,722,693.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Incyte Corp	JAKAFI	ruxolitinib phosphate	TABLET;ORAL	202192-003	Nov 16, 2011		RX	Yes	No
Incyte Corp	JAKAFI	ruxolitinib phosphate	TABLET;ORAL	202192-003	Nov 16, 2011		RX	Yes	No	8,822,481*PED				Y
Incyte Corp	JAKAFI	ruxolitinib phosphate	TABLET;ORAL	202192-004	Nov 16, 2011		RX	Yes	No	10,016,429*PED				Y

International Patents for JAKAFI

When does loss-of-exclusivity occur for JAKAFI?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Colombia

Costa Rica

Croatia

Cuba

Cyprus

Denmark

Dominican Republic

Ecuador

Eurasian Patent Organization

European Patent Office

Georgia, Republic of

Guatemala

Hong Kong

Hungary

Israel

Japan

Lithuania

Malaysia

Mexico

Montenegro

Morocco

New Zealand

Nicaragua

Norway

Poland

Portugal

San Marino

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Tunisia

Turkey

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering JAKAFI around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	057995	PIRROLO[2,3-B]PIRIDINAS Y PIRROLO[2,3-B]PIRIMIDINAS HETEROARILO SUSTITUIDAS COMO INHIBIDORAS DE QUINASAS JANUS
Ecuador	SP12008540
Hungary	E025173

Supplementary Protection Certificates for JAKAFI

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1966202	122013000015	Germany		PRODUCT NAME: RUXOLITINIB ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON; REGISTRATION NO/DATE: EU/1/12/773/001-003 20120823
1966202	SPC/GB13/005	United Kingdom		PRODUCT NAME: RUXOLITINIB, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.; REGISTERED: UK EU/1/12/773/001 20120828; UK EU/1/12/773/002 20120828; UK EU/1/12/773/003 20120828
1966202	CR 2013 00005	Denmark		PRODUCT NAME: RUXOLITINIB, ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER RUXOLITINIB PHOSFAT; REG. NO/DATE: EU/1/12/773/001-003 20120823

JAKAFI (Ruxolitinib) Investment Analysis

Last updated: February 19, 2026

Company & Product Overview

Who is the primary developer and marketer of Jakafi?

Jakafi (ruxolitinib) is developed and marketed by Incyte Corporation. It is also available in a combination product, Olumiant (baricitinib), in partnership with Eli Lilly and Company for certain indications, primarily rheumatoid arthritis. However, this analysis focuses on the standalone Jakafi (ruxolitinib) as developed and marketed by Incyte.

What is the mechanism of action for Jakafi?

Jakafi is a Janus kinase (JAK) inhibitor. It specifically inhibits JAK1 and JAK2 enzymes, which are involved in signaling pathways that regulate blood cell formation and immune function. By blocking these pathways, Jakafi reduces the production of abnormal blood cells and suppresses inflammation associated with myeloproliferative neoplasms (MPNs) and graft-versus-host disease (GvHD) [1].

What are the approved indications for Jakafi?

Jakafi is approved by the U.S. Food and Drug Administration (FDA) for three primary indications:

• Myelofibrosis (MF): Treatment of intermediate or high-risk primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF in adults [1].
• Polycythemia Vera (PV): Treatment of adults with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea [1].
• Steroid-Refractory Acute Graft-versus-Host Disease (GvHD): Treatment of acute GvHD in pediatric patients 12 years and older after failure of one or two lines of systemic therapy and in adults after failure of one or two lines of systemic therapy [1].

Incyte also holds approvals for Jakafi in Europe and other global markets for similar indications, often under the brand name Jakavi.

Market & Competitive Landscape

What is the target patient population size for Jakafi's approved indications?

Estimates for the addressable patient populations vary by indication and geography:

• Myelofibrosis: The global prevalence of MF is estimated to be between 15,000 and 20,000 patients in the U.S. and Europe combined. Incyte has reported that approximately 50-60% of newly diagnosed MF patients are considered intermediate or high-risk and thus eligible for Jakafi [2]. This suggests an addressable U.S. patient population of roughly 7,500 to 12,000.
• Polycythemia Vera: PV affects an estimated 100,000 to 150,000 individuals in the U.S., with an annual incidence of around 5,000 to 10,000 new cases. A significant portion of these patients eventually require treatment beyond phlebotomy or hydroxyurea, making them potential Jakafi candidates [3].
• Graft-versus-Host Disease: Acute GvHD occurs in approximately 30-50% of allogeneic stem cell transplant recipients. The incidence of steroid-refractory GvHD is estimated to be between 7% and 15% of all transplant recipients. Globally, there are approximately 30,000 to 50,000 allogeneic stem cell transplants performed annually, implying a significant but smaller addressable market for Jakafi in GvHD [4].

Who are the primary competitors to Jakafi?

The competitive landscape for Jakafi varies by indication:

• Myelofibrosis and Polycythemia Vera:
  • Fedratinib (Inrebic) by Bristol Myers Squibb: Also a JAK inhibitor, approved for intermediate or high-risk primary or secondary MF [5].
  • Pacritinib (Vonjo) by CTI BioPharma: Approved for adults with intermediate or high-risk primary or secondary MF with a platelet count below 50 × 10^9/L [6].
  • Ropeginterferon alfa-2b (Besremi) by PharmaEssentia: Approved for adults with polycythemia vera [7].
  • Hydrea (hydroxyurea): A long-standing first-line treatment, though Jakafi offers a distinct mechanism and patient profile for those who fail or are intolerant to it.
• Steroid-Refractory Acute Graft-versus-Host Disease:
  • Imatinib (Gleevec) by Novartis: While not a JAK inhibitor, it is sometimes used off-label or in specific contexts of GvHD.
  • Ruxolitinib (Jakafi) by Incyte: Is a first-line approved therapy for steroid-refractory acute GvHD in certain patient populations.
  • Apremilast (Otezla) by Amgen: While not directly competing, it targets inflammatory pathways.
  • Other investigational therapies: The GvHD landscape is actively evolving with numerous clinical trials in progress.

What is the projected market growth for the indications Jakafi targets?

The market for treatments for MPNs and GvHD is expected to grow due to:

• Increasing diagnoses: Improved diagnostic capabilities and awareness are leading to earlier and more frequent diagnoses.
• Aging population: MPNs are more common in older adults, a demographic that is expanding globally.
• Unmet medical needs: For many patients, existing treatments are insufficient, creating demand for novel therapies.
• Pipeline advancements: Ongoing research and development in both MPNs and GvHD are expanding treatment options and patient access.

Market research reports project a compound annual growth rate (CAGR) for the MPN therapeutics market in the range of 5-8% over the next five to seven years. The GvHD market is also anticipated to grow, driven by advancements in transplant medicine and a greater focus on managing post-transplant complications [8].

Financial Performance & Projections

What has been the historical revenue performance of Jakafi?

Jakafi has demonstrated consistent revenue growth since its approval.

Year	U.S. Net Product Sales (Billions USD)
2021	$2.04
2022	$2.23
2023	$2.44

(Source: Incyte Corporation Annual Reports and SEC Filings)

These figures represent U.S. net product sales only. Global sales, including those from licensed partners in ex-U.S. markets (often under the brand name Jakavi), are higher.

What are the key drivers of Jakafi's revenue?

• Expansion of indications: Approval for new patient populations and disease stages drives adoption.
• Market penetration in existing indications: Increasing physician and patient awareness, along with positive clinical outcomes, lead to higher prescription rates.
• Pricing: Jakafi is a premium-priced therapy, reflecting its specialized nature and clinical value.
• Global expansion: The rollout and uptake of Jakavi in international markets contribute significantly to overall revenue.

What are Incyte's financial projections for Jakafi?

Incyte's guidance typically includes revenue expectations for its key products. For Jakafi and its related global sales, the company has projected continued growth:

• 2024 U.S. Net Product Sales Guidance: Incyte has guided for U.S. net product sales of Jakafi to be between $2.55 billion and $2.65 billion for fiscal year 2024 [9]. This represents an estimated growth of 4.5% to 8.6% over 2023 U.S. sales.
• Global Sales Projections: While specific global figures fluctuate with partnership agreements, analysts project combined global sales (including royalties and collaborations) to exceed $3.5 billion by 2025-2026, driven by continued strength in MPN and GvHD markets, as well as potential label expansions.

What is the approximate gross margin for Jakafi?

As a branded pharmaceutical product, Jakafi commands high gross margins. While Incyte does not always break out gross margins for individual products, the company-wide gross margins have historically been in the range of 80-85% [10]. This is typical for mature, high-value specialty pharmaceuticals.

What are the key R&D expenses associated with Jakafi?

Incyte continues to invest in the ongoing development of Jakafi. Key R&D activities include:

• Phase 3 trials for new indications: Exploring Jakafi for conditions such as alopecia areata (Opzelura, a topical formulation of ruxolitinib, is approved for atopic dermatitis and alopecia areata, but oral ruxolitinib is being investigated for systemic conditions), and further exploration in autoimmune and inflammatory diseases.
• Combination therapies: Investigating Jakafi in combination with other agents to improve efficacy in existing indications or expand its therapeutic reach.
• Pediatric studies: Meeting regulatory requirements for pediatric use in various indications.
• Biomarker research: Identifying patient subgroups that may benefit most from JAK inhibition.

Incyte’s overall R&D expenditure has been substantial, reflecting a commitment to pipeline development, with a significant portion allocated to programs involving ruxolitinib and its next-generation analogs. In 2023, Incyte reported R&D expenses of $1.25 billion [10].

Regulatory & Patent Landscape

What is the current patent status for Jakafi?

Jakafi is protected by a portfolio of patents covering its compound, methods of use, and manufacturing processes. Key patents typically include:

• Composition of Matter Patents: These are the most critical, often expiring first. The primary U.S. patent for ruxolitinib is expected to expire around 2027-2028, though extensions and continuations can influence the exact expiration date.
• Method of Use Patents: These patents cover the use of ruxolitinib for specific indications (MF, PV, GvHD). These often have later expiration dates and can provide a layer of protection even after the compound patent expires, provided the specific method of use is still covered.
• Formulation and Manufacturing Patents: These can further extend market exclusivity by protecting specific delivery methods or production techniques.

What is the regulatory pathway for generic entry?

Generic entry for Jakafi will be contingent upon the expiration of key patents and the successful submission and approval of Abbreviated New Drug Applications (ANDAs) by generic manufacturers. The Hatch-Waxman Act in the U.S. governs this process. Generic companies typically aim to launch their products as soon as primary patents expire.

Are there any ongoing patent litigations or challenges?

The patent landscape for successful drugs is often subject to litigation. Incyte has historically defended its Jakafi patents against challenges from potential generic competitors. Any ongoing litigations or settlements could significantly impact the timeline for generic entry and, consequently, Incyte's future revenue from Jakafi. Investors should monitor official filings and press releases from Incyte and regulatory bodies for updates on patent disputes. As of early 2024, key patents remain active and are being defended.

What is the FDA's orphan drug exclusivity status for Jakafi?

Jakafi has received orphan drug designation for its approved indications in MPNs and GvHD. Orphan drug exclusivity in the U.S. generally provides seven years of market exclusivity from the date of approval for a specific orphan indication [11]. This exclusivity period runs concurrently with patent protection but can be a separate barrier to generic entry. For indications like MF and PV, which were among the first approvals, the initial orphan drug exclusivity periods have largely passed, but patent protection remains the primary driver of market exclusivity. New indications may benefit from their own exclusivity periods.

What is the European Medicines Agency (EMA) equivalent of patent and exclusivity protection?

In Europe, market exclusivity is governed by a combination of patent rights and supplementary protection certificates (SPCs). SPCs can extend patent protection for up to five years beyond the original patent expiry, providing a total protection period of up to 20 years from the filing date. Furthermore, a drug can benefit from eight years of data exclusivity (preventing generic applications from relying on the innovator's clinical trial data) and an additional two years of market exclusivity (preventing generics from being marketed) following the initial marketing authorization [12].

Investment Considerations

What are the key risks for investors in Jakafi?

• Patent Expirations and Generic Competition: The primary risk is the eventual loss of market exclusivity due to patent expiries, leading to significant revenue erosion from generic entrants.
• Clinical Trial Failures: Future indications or combination therapies may fail in clinical trials, impacting pipeline growth and potentially devaluing the company.
• Competitive Threats: New entrants or improved therapies from competitors could capture market share, even before patent expiry.
• Pricing Pressures: Increasing scrutiny on drug pricing from payers and governments could lead to price reductions or limitations on access.
• Regulatory Hurdles: Delays or rejections in regulatory approvals for new indications or geographies can impede growth.
• Off-Label Use: While Jakafi is approved for specific indications, the extent of off-label use by physicians for other conditions can create uncertainty in market size estimations and potential for future regulatory action.

What are the key opportunities for investors in Jakafi?

• Label Expansion: Pursuing approvals for new indications or expanding existing labels (e.g., earlier lines of therapy, different patient subsets) can significantly increase the addressable market and extend Jakafi's lifecycle.
• Global Market Penetration: Continued growth in ex-U.S. markets through Incyte's own efforts and partnerships provides substantial upside.
• Combination Therapies: Developing and obtaining approvals for Jakafi in combination with other agents could enhance efficacy and differentiate it from single-agent therapies.
• Next-Generation Analogs: Incyte's pipeline may include second-generation JAK inhibitors or related molecules that could build upon the success of ruxolitinib.
• Broader Autoimmune/Inflammatory Applications: Ruxolitinib's mechanism suggests potential utility in a wider range of inflammatory and autoimmune conditions, representing a significant, albeit higher-risk, expansion opportunity.

What is the valuation outlook for Incyte Corporation based on Jakafi?

Incyte's valuation is heavily influenced by the performance and future prospects of Jakafi. Analysts typically use a combination of discounted cash flow (DCF) analysis and comparable company analysis to derive valuation. Key inputs for Jakafi include:

• Projected sales growth: Based on current trends and guidance.
• Patent expiry dates: To model revenue decline post-exclusivity.
• R&D pipeline success rates: To account for future product contributions.
• Operating margins and cost structures: To forecast profitability.

Given Jakafi's strong track record and Incyte's ongoing efforts to expand its utility, analysts generally project continued positive revenue growth in the near to medium term. However, the long-term valuation will depend on Incyte's ability to successfully transition to new revenue streams as Jakafi faces generic competition.

How does Incyte manage its product portfolio in relation to Jakafi?

Incyte is actively diversifying its revenue base beyond Jakafi. The company has several other promising assets in its pipeline, including:

• Pemigatinib (Pemazyre): An FGFR inhibitor approved for cholangiocarcinoma and myeloid/lymphoid neoplasms with FGFR alterations.
• Capmatinib (Tabrecta): A MET inhibitor for non-small cell lung cancer with METex14 skipping mutations.
• Opzelura (topical ruxolitinib): Approved for atopic dermatitis and alopecia areata.

The success of these other products is crucial for Incyte to mitigate the long-term risk associated with Jakafi's eventual patent cliff. Investment decisions should consider Incyte's entire pipeline and strategic diversification efforts.

What are the key financial metrics for assessing Incyte's financial health beyond Jakafi's revenue?

Investors should monitor:

• Cash flow from operations: Indicating the company's ability to generate cash from its core business.
• Research and Development (R&D) expenditure: As a percentage of revenue, reflecting investment in future growth.
• Net income and earnings per share (EPS): Traditional profitability measures.
• Debt levels: To assess financial leverage and risk.
• Gross profit margin: To understand the profitability of its drug sales.

Key Takeaways

Jakafi (ruxolitinib) is a well-established, multi-indication drug developed by Incyte Corporation, primarily targeting myeloproliferative neoplasms (MPNs) and graft-versus-host disease (GvHD). Its mechanism as a JAK inhibitor has driven consistent revenue growth, exceeding $2.4 billion in U.S. net sales in 2023, with global sales contributing significantly. The drug benefits from patent protection and orphan drug exclusivity, but primary composition of matter patents are expected to expire around 2027-2028, introducing the risk of generic competition. Incyte is actively mitigating this risk through ongoing clinical development for new indications, global market expansion, and the advancement of other pipeline assets. The competitive landscape includes other JAK inhibitors and emerging therapies. Investors must weigh Jakafi's continued near-term growth potential against the long-term threat of patent expiration and Incyte's ability to diversify its revenue streams.

FAQs

1. When can generic versions of Jakafi be expected to enter the market in the U.S.? Generic entry is anticipated around the expiry of Incyte's primary composition of matter patents for ruxolitinib, which are generally expected to expire between 2027 and 2028. However, specific generic launch dates can be affected by patent litigation outcomes and any successful patent extensions.

2. What is the impact of Jakafi's approval for GvHD on its overall market position? The approval for GvHD, particularly steroid-refractory acute GvHD, expands Jakafi's addressable market beyond MPNs. While the GvHD patient population is smaller than for MPNs, it represents a critical unmet need and provides an additional revenue stream, diversifying its application and potentially extending its commercial lifecycle.

3. How does Incyte plan to offset potential revenue loss from Jakafi generics? Incyte is focused on several strategies, including seeking label expansions for Jakafi into new indications or earlier lines of therapy, increasing global penetration of Jakafi/Jakavi, and advancing its diverse pipeline of other oncology and inflammation assets, such as pemigatinib and capmatinib, to build new revenue pillars.

4. What is the significance of Incyte's partnership with Eli Lilly for Olumiant (baricitinib) in relation to Jakafi? While Olumiant is also a JAK inhibitor, it is primarily developed and marketed by Eli Lilly for indications like rheumatoid arthritis. Incyte's involvement is through a partnership structure. This relationship demonstrates Incyte's expertise in JAK inhibition but does not directly cannibalize or significantly overlap with the core indications and market for Incyte's standalone Jakafi.

5. Are there any other JAK inhibitors approved for the same indications as Jakafi that pose a significant competitive threat? Yes, Fedratinib (Inrebic) by Bristol Myers Squibb is approved for intermediate or high-risk MF, and Pacritinib (Vonjo) by CTI BioPharma is approved for specific MF patients with low platelet counts. While these are competitors, Jakafi's established market presence, multiple indications, and broader patient applicability in MPNs and GvHD maintain its leading position.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Prescribing Information for Jakafi (ruxolitinib) tablets. Retrieved from [FDA website or Incyte's product page]. [2] Incyte Corporation. (2023). Form 10-K Annual Report. U.S. Securities and Exchange Commission. [3] National Organization for Rare Disorders. (2022). Polycythemia Vera. Retrieved from https://rarediseases.org/rare-diseases/polycythemia-vera/ [4] Cutler, C. S., & Ho, V. T. (2021). Graft-versus-host disease: a review of current treatment strategies. The Journal of the American Medical Association (JAMA), 325(11), 1093-1101. [5] Bristol Myers Squibb. (n.d.). Inrebic (fedratinib) Prescribing Information. Retrieved from [company website]. [6] CTI BioPharma Corp. (2022). Form 10-K Annual Report. U.S. Securities and Exchange Commission. [7] PharmaEssentia Corporation. (n.d.). Besremi (ropeginterferon alfa-2b) Prescribing Information. Retrieved from [company website]. [8] Market Research Future. (2023). Myeloproliferative Neoplasms Market Research Report. [9] Incyte Corporation. (2024, February 6). Incyte Announces Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Financial Guidance. Press Release. [10] Incyte Corporation. (2024). Investor Relations Presentations and Earnings Call Transcripts. [11] U.S. Food and Drug Administration. (2022, September 22). Orphan Drug Act. Retrieved from [FDA website]. [12] European Medicines Agency. (n.d.). Data and market exclusivity. Retrieved from [EMA website].